C4 Therapeutics Inc

For the period ended Oct 31, 2024. Filed Oct 31, 2024.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Oct 31, 2024 · Filed Oct 31, 2024

Use the contents to explore the available documents and sections.

CCCC$3.10+5.1%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

EX-99.1 · COLLABORATIONS:

COLLABORATIONS:

Delivered Second Development Candidate to Biogen. In September 2024, C4T earned an additional $8 million milestone payment after Biogen accepted delivery of a second development candidate in an undisclosed indication. Biogen is responsible for all future clinical development and commercialization for this program. This marks the final development candidate under this strategic collaboration.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.